FGFR-Portal

The FGFR-Portal was set up to offer pathologists, consultants working in other disciplines, and oncologists orientation at the interface between biomarker tests and therapy options. The Portal hosts a biomarker-based therapy algorithm. This algorithm is based both on current medical guideline recommendations as well as the latest scientific findings, and provides full details of the underlying investigations.

QuIP has set itself the task of accompanying pathologists in Germany and Europe in optimizing their examination results and to support them in all relevant professional and organizational activities in quality assurance.

FGFR pathway alterations have been implicated in approximately 7 % of cancer entities. Due to the proliferative behavior of FGFR alterations in cancer, FGFR inhibitors have emerged as potential targeted therapeutic agents in recent years. The promising results of FGFR inhibitors in advanced unresectable cholangiocarcinoma harboring FGFR2 fusions and in metastatic urothelial carcinoma with FGFR2 and FGFR3 genetic alterations led to their accelerated approval in cholangiocarcinoma and urothelial carcinoma.

While specific biomarker-tested therapies for advanced altered urothelial and cholangiocarcinoma have been approved, additional studies are being conducted on various tumor entities which could expand the use of this specific inhibitor for different types of cancers. The portal will provide comprehensive information on different FGFR alterations and their detection, serving as an interdisciplinary resource for diagnostics, molecular pathology and biomarker determination for a wide range of tumor entities. It includes algorithms that offer detailed information on tests, corresponding results and different therapy options. In parallel, users will be able to access the portal via specific tumor entities or via approved drugs.

The underlying sources from the research literature consulted by the portal content authors are cited as a list on a separate “References” tab on each of the relevant algorithm pages. In each case, these research references and citations reflect the current state of progress on the part of the scientific experts, and will be updated/amended regularly by the team as necessary.

Data protection in Germany prevents QuIP from publicly sharing the portal and the link to the website. Only the introduction can be seen on the portal start page, all other content is only available to medical professionals.

Registered QuIP users will automatically find a link to the FGFR-Portal after logging in on the QuIP homepage. All physicians who have DocCheck access will also have access to the FGFR-Portal. All other interested parties without a QuIP account or DocCheck access can request access to the portal by sending an e-mail to QuIP. An access code will be provided once the requestor’s access requirements are checked.

The QuIP is supported by Incyte and Janssen-Cilag.

Status: June 2023